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Introduction
FMF diagnosis is made clinically and may be supported
by identifying mutations in the MEFV gene. The most
commonly used diagnostic criteria for FMF are those of
Tel Hashomer and the Livneh criteria, which have been
established in the Jewish adult population. Recently, a
Turkish group (Yalçınkaya-Özen) proposed new criteria
for diagnosis of FMF in children.
Objectives
We aimed to analyze the validity of the Turkish diag-
nostic criteria for pediatric FMF in a large international
registry.
Methods
The study group is consisted of 339 FMF patients diag-
nosed according to Tel Hashomer criteria. A control
group of 377 patients were diagnosed with other peri-
odic fever syndromes including MKD, TRAPS, CAPS,
PFAPA and undefined periodic fever. Both groups were
evaluated according to the Tel Hashomer, Livneh cri-
teria and the new set of pediatric diagnostic criteria.
Results
The sensitivity and specificity of the Tel Hashomer
criteriaand Livneh criteria in our study were 35.1% and
97.7%, 77.6% and 45.9%, respectively. The presence of
two or more of these new five criteria diagnosed FMF
with a high sensitivity of 87.4% and a negative predictive
value (NPV) of 74.8%. When we used at least three
pediatric criteria, the discrimination of the diseases
other than FMF reached the highest specificity of 88.2%
and the positive predictive value (PPV) of 82.9% at the
expense of sensitivity. If all the new sets of criteria were
met, the specificity and sensitivity were 99.6% and 5.6%,
respectively with a PPV of 94.1% and an NPV of 49.2%.
Our study showed that ethnicity had no impact on the
validation.
Conclusion
The Tel Hashomer diagnostic criteria were found to have
high specificity (97.7%) for the diagnosis of FMF, whereas
pediatric criteria had a higher sensitivity (87.4%) if at
least two out of its five criteria were met. The small
number of patients with amyloidosis or erysipelas like
erythema and the response to colchicine therapy consti-
tuted the drawbacks in assessing the patients with Tel
Hashomer criteria. The Livneh criteria were also found to
have high specificity (45.9%) for the discrimination of the
diseases other than FMF, whereas pediatric criteria were
more precious than the Livneh criteria because of that
it’s higher sensitivity rate for FMF diagnosis in pediatric
patients. Our analysis showed that the pediatric criteria
had performed better in diagnosing patients with FMF in
childhood in respect to Tel Hashomer and the Livneh
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